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doi:10.1016/j.ejvs.2008.07.010Abstract Objective: To evaluate single center results of the Zenith stent-graft for elective
abdominal aortic aneurysm repair.
Methods: Data from all patients treated with a Zenith graft between March 1999 and
December 2006 were retrospectively analyzed from a prospective database. Outcome
measures were technical success, all-cause and aneurysm related mortality, late complica-
tions, and re-interventions.
Results: A total of 234 patients were included, of which 216 were male. Mean age was
72.1 6.9 years. Mean diameter of the aneurysm was 60.9 10 mm. Technical success rate
was 98.3%. Thirty day mortality was 1.7%. Median follow-up was 26.9 months (range,
1e104). Overall survival was 92.2  1.8% at 1 year, 87.2  2.3% at 2 years, and 69.9 4.6%
at 5 years. During follow-up, one aneurysm ruptured due to limb disconnection, which was
treated by bridging stent-grafting. Re-interventions were performed in 9.2% of the patients,
with 79% by endovascular means. There was no mortality related to re-intervention.
Conclusions: Endovascular abdominal aortic aneurysm repair with the Zenith device provides
excellent results with a low risk for aneurysm-related death and rupture, and a low re-inter-
vention rate in the mid-term.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.0 361 33 82; fax: þ31 50 361
mcg.nl (W.T.G.J. Bos).
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Although early benefits of endovascular abdominal aortic
aneurysm repair (EVAR) have been demonstrated in two
randomized trials, the number of late complications and re-
interventions remains an issue of debate.1,2 First genera-
tion devices were associated with high rates of lated by Elsevier Ltd. All rights reserved.
654 W.T.G.J. Bos et al.complications.1,3 Later, the rate of secondary interventions
seemed to decline, which was readily attributed to
improved stent-graft design and better patient selection.4,5
The Zenith (Cook Inc, Bloomington, IN, USA) stent-graft
is a third generation device that underwent very few
changes over the years. It is available both in a custom-
made two-part bifurcated device and in a standard three-
part (aortic bifurcationþ two iliac limbs) device. Although
it has been used in more than 15 000 patients worldwide,
there are still only few reports regarding the mid- and long-
term follow-up.
The aim of this study was to report our single centre
experience with the Zenith stent-graft.
Materials and Methods
The EVAR programme in our University Medical Center
started in 1996. In the first years devices were mainly
chosen based upon availability. From 1999 onwards several
devices were commercially available allowing us to tailor
device selection according to anatomical features of the
aneurysm (e.g. Talent [Medtronic World Medical, Sunrise,
FL, USA] for proximal necks with a large diameter, Excluder
[W.L. Gore and Associates, Flagstaff, AZ, USA] for narrow
and angulated iliac arteries because of the flexibility of the
device, Zenith [Cook Inc, Bloomington, IN, USA] for short
proximal necks in view of the suprarenal fixation of the
bare stent with hooks and barbs). Since 2001 we have the
availability of a full range of Zenith devices in stock. This,
together with the versatility of the device in terms of distal
diameter (10e24 mm) and lengths, is the reason why many
patients were treated with a Zenith device.6,7
Patients
Between March 1999 and December 2006, a total of 379
patients underwent elective EVAR. The Zenith graft was
selected in 234 patients. The device incorporates self-
expanding stainless-steel Z stents attached to a polyester
graft material. Features of the device are the suprarenal
fixation and a controlled release mechanism of the bare top
stent.7,8
Work-up
Pre-operative work-up consisted of a multi-slice computed
tomography (CT) scan to evaluate the anatomy of the
proximal and distal landing zones and the access through
the femoral arteries. In selected cases, an additional
angiography was performed. Evaluation of the indications
for surgery and selection of the device was done by a team
of senior staff members including an interventional
radiologist.
Procedure
All procedures were performed in an operating theatre
using a mobile image intensifier. Access to the femoral
arteries was usually performed through surgical dissection,
preferably under local anaesthesia. A description of the
technique has been reported elsewhere.9 Embolization ofan internal iliac artery (IIA), if needed, was routinely per-
formed during the same procedure. Patients received
antibiotic prophylaxis (cefazoline 1 g) and heparin (5000 IU)
intravenously.
Follow-up
From 1996 to January 1999, duplex ultrasound scanning,
CTA (or MRA for suitable devices) and multiplanar abdom-
inal radiography were performed before discharge of the
patient. Follow-up included CTA or MRA, duplex ultrasound,
and abdominal X-ray at 1, 3, 6, 12, 18, and 24 months, and
yearly thereafter. From 1999 on, based on our clinical
experience and emerging literature, but also due to logis-
tical and stochastic burden for the patient, the protocol
was simplified: duplex ultrasound scanning and multiplanar
abdominal radiography were done before discharge. At
1 month, a contrast-enhanced CT-scan was performed.
Routine follow-up thereafter consisted of duplex ultra-
sound scanning and multiplanar abdominal radiography at
6 months, 1 year and annually thereafter. CT-scan (or
angiography) was only done on indication (endoleak,
growth of aneurysm, migration> 5 mm, kinking). All
patients treated with the Zenith device were followed with
the new protocol.10e12 All patients were put on antiplatelet
therapy after the procedure.
Definitions and statistics
Data were collected prospectively on intention-to-treat
basis but analysed in a retrospective manner with SPSS 12.0
(SPSS, Chicago, IL, USA). Reporting standards for endovas-
cular aortic aneurysm repair were used for definitions and
analysis of endpoints.13 Primary endpoints were technical
success, all-cause and aneurysm related mortality and
aneurysm rupture. The cause of death was determined by
assessment of patient charts and by contacting the general
practitioners and patients’ relatives if necessary. Aneurysm
related mortality was defined as death resulting from
aneurysm rupture (as proven by autopsy, surgery or CT
scan) or any death occurring within 30 days after the orig-
inal procedure or a re-intervention. In case an autopsy was
not available, we classified the death as probably unrelated
if the clinical picture was consistent and documented with
reliable observations during the terminal illness. When
these criteria could not be met, the cause of death was
considered indeterminate. Secondary endpoints were late
complications including migration (>5 mm), endoleak,
aneurysm sac diameter changes and re-intervention.
Primary technical success was defined as a successful
introduction and deployment of the device in the absence
of conversion or intra-operative mortality, type I or III
endoleaks, or graft limb occlusion. When unplanned endo-
vascular or surgical procedures were necessitated during
the procedure or within 24 h, the terms assisted primary or
secondary technical success, respectively, were used. Re-
intervention was defined as any endovascular (trans-
femoral) or open surgical intervention (transfemoral or
transabdominal) performed after the initial EVAR in order
to maintain or restore the function of the endograft. When
more than one re-intervention was necessary during follow-
up, the classification of primary, secondary and tertiary
Table 2 Perioperative data
Operating time (min) 116.4 29.5
Fluoroscopy time (min) 9.0 8.6
Amount of contrast (mL) 153.8 55.1
Blood loss (mL) 156.7 107
Local anaesthesia
(no. of patients)
175
Regional anaesthesia
(no. of patients)
36
General anaesthesia
(no. of patients)
23
Length of stay (days) 4.6 3.9
Results of the Zenith Stentgraft 655re-intervention was used.10 Variables were expressed as
mean standard deviation or median (range) by skewed
data. Time-to-event variables were studied with Kaplane
Meier survival analysis.
Results
A total of 234 patients underwent elective EVAR with the
Zenith stent-graft. There were 216 male patients. Mean age
was 72.1 6.9 years. Indications for surgery and co-
morbidities are summarized in Table 1. Mean diameter of
the aneurysm sac was 60.9 10 mm (range 45e150 mm).
Two aneurysms were smaller than 50 mm; the first was
45 mm (anastomotic aneurysm after tube-graft with rapid
growth) the second 47 mm but with growth of 1 cm in 6
months. Forty-nine aneurysms had a diameter between 50
and 55 mm. Median neck length was 22.5 mm (range 10e
100). One hundred and three patients (44%) had a neck
length between 10 and 20 mm.
Different types of the Zenith device were used. A
bifurcated graft was used in 220 patients (94%) including
156 patients with a Tri-Fab (three-part) prosthesis and 64
patients with a Custom-Made (two-part) prosthesis. Ten
patients were treated with an aorto-uni-iliac device with
a femoralefemoral cross-over bypass and three patients
with a tube-graft. One patient did not receive an endograft
(see below). Procedural details are shown in Table 2. In 13
patients a combination of a Cook body with Excluder limb(s)
was used.
In 23 (10%) patients, planned additional intra-operative
endovascular manoeuvres were performed. In 14 patients
embolization of side branches was performed (13 IIA and
one IMA). In five patients a self-expandable stentTable 1 Patient co-morbidity and indication for surgery
N %
ASA classification
ASA II 96 41.0
ASA III 128 54.7
ASA IV 10 4.3
Co morbidity
Hypertension 134 57.3
Chronic obstructive
pulmonary disease
68 29.1
Coronary artery disease 114 48.7
Congestive heart failure 14 6.0
Arrhythmia 32 13.7
Diabetes mellitus 34 14.5
Hypercholesterolemia 82 35.0
Renal insufficiency
(creat> 150 mmol/l)
17 7.3
Prior abdominal
surgery (laparotomy)
46 19.7
Indications for surgery
Infrarenal aneurysm 212 90.6
Aorto-iliac aneurysm 14 6.0
Anastomotic aneurysm 4 1.7
Inflammatory aneurysm 4 1.7(Wallstent, Boston Scientific, Natick, MA, USA) was posi-
tioned inside a limb to correct kinking in order to avoid
occlusion. Four patients underwent percutaneous trans-
luminal angioplasty (PTA) intra-operatively (three iliac
arteries and one renal artery).Technical success, in-hospital mortality and
morbidity
Primary technical success rate was 95.3% (223/234
patients). The primary assisted technical success rate was
97.4% (228/234 patients). Five patients required unplanned
additional stent-graft components: Three patients had
a type I endoleak at the completion angiography which was
corrected with a proximal extension, and two patients
received a bridging stent-graft to correct insufficient
overlap zones. Secondary technical success rate was
98.3%(230/234 patients): One patient underwent a re-
intervention within 24 h to correct a graft limb thrombosis;
in the second patient a femoral artery graft interposition
(for femoral artery aneurysm) occluded at day 1, which
required immediate revision. In four patients (1.7%) the
procedure was technically unsuccessful. In one patient the
delivery system could not be introduced through the narrow
and calcified iliac arteries. The patient was judged inop-
erable for an open procedure due to inoperable coronary
disease. He died 1 year later due to myocardial infarction.
In three patients a type I endoleak was seen at completion
angiogram. Two patients had a proximal endoleak, which
was treated with re-ballooning. After ballooning, a small
endoleak persisted which was initially accepted. The third
patient had a small distal endoleak. The IIA on the opposite
side being already occluded, it was decided not to occlude
the second IIA by overstenting it. In all three cases the
endoleaks disappeared within 1 month.
Overall 30 day mortality was 1.7% (four patients). Two
patients died of myocardial infarct at 1 and 7 days,
respectively. Another patient died at day 8 due to cerebral
haemorrhage in a metastasis. The fourth patient died at
home at day 15 after an uneventful procedure, most likely
to myocardial infarction. According to reporting standards
for endovascular aortic aneurysm repair, there were five
severe, six moderate, and 28 mild surgical complications in
39 patients (16.7%).13 Details of these complications are
shown in Table 3.
Table 3 Early complications
Complication (1) Mild % (2) Moderate % (3) Severe %
Cardiac 0 3 1.3 2 0.8
Pulmonary 0 0 1 0.4
Renal insufficiency 3 1.3 1 0.4 0
Cerebrovascular 0 0 1 0.4
Access site infection 3 1.3 0 0
Access site hematoma 16 6.8 0 0
Access site false aneurysm 0 1 0.4 0
Urinary 5 2.1 0 0
Postoperative endograft
limb obstruction
0 1 0.4 1 0.4
Failed deployment 1 0.4 0 0
Total 28 6 5
656 W.T.G.J. Bos et al.There were three re-interventions within the hospital
stay. Two occurred within 24 h as mentioned above. In the
third patient, who underwent a percutaneous approach
(closure with a Prostar, Abbott Vascular, Redwood City, CA,
USA) a false aneurysm was surgically repaired on the sixth
postoperative day. All reinterventions are listed in Table 4.
Follow-up
Initial follow-up was available in all 229 surviving treated
patients (four deaths, one aborted treatment). Median
follow-up was 26.9 months (range, 1e104). However, 26
patients were lost to follow-up between 12 and 35 months.
Reasonswere co-morbidity in combination of advancedage in
22 patients, and moving away to other area in four patients.
Late mortality
During follow-up, 43 (18.8%) patients died between 2 and
96 months (median 23 months). Autopsy findings confirmed
that death was unrelated in six patients. In 33 patients,
death was classified as probably unrelated in view of
consistent clinical findings: malignancy (15), cardiac (5),
pulmonary disease (5), stroke (5), bleeding gastric ulcer
(2), and ischemic bowel (1). Finally four patients died
without known cause and were classified as indeterminate
aneurysm related deaths. Overall survival was 92.2 1.8%
at 1 year, 87.2 2.3% at 2 years, 81.1 3% at 3 years and
69.9 4.6% at 5 years (Fig. 1).
Endoleaks, device migrations, and graft limb
occlusions
During follow-up endoleaks of any type were diagnosed in
50 patients (21.8%). There were seven high-pressure
endoleaks (type I or type III).
Type I endoleaks were seen in five patients (2.2%). A
proximal type I endoleak occurred in two patients. In the
first patient, the graft did not seal sufficiently in an angu-
lated proximal neck. In the second patient, a complete
disconnection between the bare stent and the graft
occurred and was diagnosed at 5-years follow-up. Both
required treatment as discussed below. A distal type Iendoleak occurred in three patients. In two patients, this
was due to extension of disease in dilated common iliac
arteries. In the third patient, a limb was initially not posi-
tioned far enough inside the common iliac artery. All three
cases required endovascular re-intervention, two of them
in the acute setting.
Type III endoleaks were seen in two patients (0.9%). Both
were disconnections of the contra-lateral limb, one in
a 10 cm large aneurysm. Both were repaired by endovas-
cular means, one in the acute setting, and the other in the
elective setting.
Type II endoleaks were diagnosed in 43 patients (18.8%).
In 24 (56%) patients spontaneous resolution occurred,
mainly during the first 6 months. In 11 patients the type II
endoleak persisted but no treatment was initiated until
now. In eight patients with a type II endoleak, five in
conjunction with a growing aneurysm, a re-intervention
was performed. No patient with a type II endoleak
ruptured. Aneurysm sac growth> 5 mm was seen in 7 (3.1%)
patients (five with type II endoleak, two without evidence
of endoleak). Overall, mean AAA sac diameter decreased
from 60.6 10.3 to 49.0 12 mm.
Proximal migration of more than 5 mm without endoleak
occurred in three (1.3%) patients. None of these three
patients required treatment. This is without including the
mentioned patient with the disconnection of the bare stent.
Four (1.7%) patients experienced graft limb occlusions,
including the occlusion on day 1. Three patients required
treatment as mentioned below. The last patient experi-
enced mild claudication only and was not treated.Re-interventions
Twenty-nine re-interventions were performed in 21 (9.2%)
patients, including the three in-hospital re-interventions.
Six patients underwent acute re-intervention. Three
patients of which one was in shock were admitted with
sudden onset of pain. Investigation showed a distal type I
endoleak in two cases (one ruptured, one non-ruptured)
and one non-ruptured type III endoleak. All three cases
were treated by endovascular means. Recovery was
uneventful. The other three acute re-interventions were
done for graft limb occlusions. Details are shown in Table 4.
Table 4 Indication and procedures for re-intervention
Pt. number Prosthesis Timing Indication
for primary
re-intervention
Procedure Interval Secondary
re-intervention
Interval Tertiary
re-intervention
Interval
109 CM A Occluded iliac limb Thrombectomy,
balloon-expandable stent
0
488 TF E False aneurysm CFA Suture CFA 0
492 TF A Occluded CFA Thrombectomy,
dacron interposition
0
367 TF E Type II endoleak Coil embolization
lumbar branch
8
264 CM E Type II endoleak Unsuccessful coil
embolization
lumbar branch
8 Coil embolization
IMA
21
468 TF E Stenosis iliac limb Balloon-expandable
stent
10
449 TF E Abces proximal part of
prosthesis
CT guided drainage 10
445 TF E Type II endoleak Unsuccessful coil
embolization lumbar
branch
10
129 TF E Type II endoleak Coil embolization
IMA and IIA, and limb
extension to EIA
11
217 TF E Distal type I endoleak Extension limb 14
154 TF A Type III endoleak
with acute non-
ruptured AAA
Bridging stentgraft 15 Occlusion
bridging
stentgraft;
ileofemoral
cross-over
19
332 TF E Type II endoleak Unsuccessful coil
embolization
lumbar branch
22 Laparotomy,
conversion
to bifurcated
graft
16 2
135 CM E Proximal type I
endoleak
Fenestrated
aortic cuff
24 Laparotomy,
suture ligation
lumbar artery
4 Laparotomy, removal
disconnected limb,a
ileofemoral cross-over
10
228 TF A Distal type I endoleak
with acute ruptured
AAA
Extension limb 29
206 CM A Distal type I endoleak
with acute non-
ruptured AAA
Extension limb 36 Increasing growth;
laparotomy showed
hygroma; sac closed
8
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Figure 1 Overall patient survival over mid-term follow-up.
658 W.T.G.J. Bos et al.One semi-acute reintervention was required for
a possibly infected stent-graft. The patient presented with
general malaise, fever and diffuse abdominal and lower
back pain 10 months after the EVAR procedure. CT-scan
showed fluid collections behind the proximal part of the
endovascular graft and dorsal to the aorta. CT-guided
translumbar needle aspiration of these collections yielded
growth with Listeria monocytogenes. Radiological drainage
and prolonged antibiotic treatment resulted in favourable
outcome at midterm follow-up (25 months) with preserva-
tion of the endograft.14 At present, the patient is symptom
free, with normal CT-scan findings and infection
parameters.
Details of all re-interventions are shown in Table 4. In
total there were 23 (79%) transfemoral and six (21%)
transabdominal re-interventions. The transabdominal
procedures included one ileofemoral cross-over bypass for
graft limb occlusion, and five laparotomies to ligate lumbar
arteries (type II endoleak with growing aneurysm). In one of
these cases it proved impossible to control the bleeding and
it was decided to perform a conversion. The patient’s
recovery was uneventful. The primary re-intervention was
successful in 15 (71.4%) patients. However, in six patients,Numbers at risk:
216 190 153 136 98 83 66 62 51 42 26 20 14
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Figure 2 Cumulative intervention free survival rates.
Results of the Zenith Stentgraft 659new complications occurred and resulted in secondary and
tertiary re-interventions. There was no mortality related to
re-intervention. The cumulative intervention-free survival
is shown in Fig. 2.Discussion
This cohort study is the largest published single center
study with the Zenith stent-graft in Europe. Its use appears
to be safe with a secondary technical success rate of 98.3%
and 1.7% surgical mortality in the whole cohort (i.e.
including low- and high-risk patients). The durability of the
device, measured by the late related mortality and re-
intervention rate at mid-term follow-up, is excellent. In
this series, re-intervention rate was 9.2% including three
early re-interventions. Late re-interventions were required
in 18 (7.9%) patients for a re-intervention free survival rate
of 95.9 1.3% at 1 year, 93.4 1.8% at 2 years and
85.8 3.5% at 5 years follow-up. This is a significant
improvement compared to earlier results of EVAR, with
reported late re-intervention rates between 11 and 18%.1,3
Several other more recent reports on the Zenith graft
confirm our findings with re-intervention rates ranging
between 6.8 and 12.5% (Table 5).5,15e20 Although better
patient selection and increased experience with EVAR
probably play a role, graft design is also contributing to
durability and longevity of the procedure.21 The Zenith
graft provides a secure proximal fixation by combining
transrenal fixation with hooks and a high radial force.
Proximal migration carried a low incidence (1.7%) during
follow-up in this series. Three grafts migrated between 5
and 10 mm but are now stable with still sufficient sealing in
a longer neck (18, 21, and 24 mm). In a fourth patient with
an older type of attachment of the bare stent with the graft
material, the bare stent disconnected completely which
required a bridging cuff. This problem was solved by the
manufacturer by strengthening the attachment between
the bare stent and the stent-graft. The low incidence of
proximal migration was confirmed by other series.17,18
An advantage of the Tri-Fab system is versatility with
regard to length and diameter issues distally. It makes
exact positioning at the distal landing zone possible,
because the required iliac leg extensions can be measured
and selected after insertion of the main body. ObviouslyTable 5 Literature overview of reports on the Zenith graft, use
Authors Year No. patients SC/MC 30 days
mortality (%
Greenberg18 2001 528 MC 0
Resch20 2001 53 SC 0
Abraham16 2002 116 SC 0.9
Alric17 2002 88 SC 3.4
Greenberg15 2004 200 MC 0.5
Hinchliffe19 2004 269 MC 4.1
Lalka5 2005 136 SC 0
This study 2008 234 SC 1.7
SC/MC: single-center or multi-center study.
nm: Not mentioned.this necessitates the immediate availability of back-up
devices. Over time, we have learned to take advantage of
this option.
A theoretical disadvantage in a three-part modular
device is the higher risk of disconnection and subsequent
type III endoleak.7,17 In our series we saw only two
disconnections (0.9%), both in the contra lateral limb, but
never in an ipsilateral limb which is usually positioned with
a two-to-three stent overlap. This urged us to consider
a one-and-a-half stent overlap for the contra lateral limb.
Since then no more disconnections were seen. In retro-
spect, both disconnections were predictable from the
X-rays made during routine follow-up, since these showed
initial minor migration. Unfortunately this was missed both
times, which stresses the importance of a thorough review
of follow-up examinations. With earlier diagnosis, i.e.
before full disconnection, endovascular repair with
a bridging stent-graft would have been much easier. After
disconnection, catheterization can sometimes prove
tedious in view of misalignment.
The limbs of the Zenith prosthesis are prone to kinking in
tortuous and narrow iliac arteries, due to their interrupted
stent design.15,17,22,23 In our study, we encountered only
four (1.7 %) graft-limb occlusions. This relatively low rate
can be explained by a meticulous choice of stent-graft and
the tactical approach in each patient. In patients at risk for
iliac limb occlusion (tortuous and/or narrow vessels) a self-
expandable stent positioned inside the Zenith graft limb
should avoid kinking and subsequent occlusion.23 We
applied this with success in five patients. Another option in
case of a longer proximal neck (in our opinion> 20 mm) is
to use a device with infrarenal fixation but with more
flexible iliac limbs (e.g. Gore Excluder). As mentioned
above, in case of aneurysms with a short neck and tortuous
iliac arteries, we did not hesitate to use a combination of
a Cook Zenith Tri-Fab body with Gore Excluder limbs. The
Gore Excluder limbs with their proximal diameter of 16 mm
do seal well inside the gates of the Zenith Tri-Fab body. For
completeness, we report that none of these 13 patients
required re-intervention.
In our series, re-intervention rate was low, and impor-
tantly, not associated with mortality. It is known that trans-
abdominal and extra-anatomic procedures to treat
complications after EVAR do carry a higher risk of mortality
and morbidity.4 In our series 79% of re-interventions wered in over 50 patients, published from 2001 on
)
Re-intervention
(%)
Migration
(%)
Occlusion
(%)
FU
(months)
nm 1.5 0.9 18
9.4 0 1.8 7
10.3 0 0.9 10.3
6.8 1.1 3.4 20.6
11 2 1.5 nm
7.5 0.4 Ns 12.2
12.5 1.5 2.9 36
9.2 1.3 1.7 26.9
660 W.T.G.J. Bos et al.performed by transfemoral approach. This is certainly one
explanation for the 0% mortality. Other possible explana-
tions are diagnosis and treatment of complications at an
early stage, in order to carry out the procedure in an
elective setting.
In conclusion, the Zenith device is a safe and durable
third-generation device, with a low re-intervention rate.
Over the years, the Zenith graft gradually became our first
choice, not only in short necks, in view of the excellent
results and the grafts’ versatility.
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